Last update 19 Nov 2026

Satralizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Humanised anti-IL-6 receptor monoclonal antibody, Sapelizumab, Satralizumab (Genetical Recombination)
+ [13]
Target
Action
antagonists
Mechanism
Interleukin-6 receptor antagonists
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
Canada (01 Jun 2020),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Graves Ophthalmopathy
United States
16 Oct 2026
AQP4-IgG positive Neuromyelitis optica spectrum disorder
Australia
17 Nov 2020
Neuromyelitis Optica
Canada
01 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myelin oligodendrocyte glycoprotein antibody-associated diseaseNDA/BLA
United States
01 Jul 2026
Myelin oligodendrocyte glycoprotein antibody-associated diseaseNDA/BLA
European Union
01 Jul 2026
Myelin oligodendrocyte glycoprotein antibody-associated diseaseNDA/BLA
Japan
01 Jul 2026
Autoimmune EncephalitisPhase 3
United States
24 Apr 2023
Autoimmune EncephalitisPhase 3
United States
24 Apr 2023
Autoimmune EncephalitisPhase 3
China
24 Apr 2023
Autoimmune EncephalitisPhase 3
China
24 Apr 2023
Autoimmune EncephalitisPhase 3
Japan
24 Apr 2023
Autoimmune EncephalitisPhase 3
Japan
24 Apr 2023
Autoimmune EncephalitisPhase 3
Argentina
24 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Neuromyelitis Optica
AQP4-IgG-positive
181
gsklgvgrvo(fjtyuzyyzf) = lrrdgntcxg szsmmjvnqp (eldzsejbdn )
Positive
23 Sep 2026
gsklgvgrvo(fjtyuzyyzf) = rguzyykgqr szsmmjvnqp (eldzsejbdn )
Not Applicable
10,307
ibupdzfufd(hgoyirupom) = Among 66 patients who switched to biologics, median ARR decreased from 0.51 during the pre-biologic period (median observation period, 654 days) to 0 during both the first (318 days) and second (280 days) biologic treatment periods. In patients who discontinued biologics (n=165), median ARR decreased from 0.51 during the pre-biologic period (median follow-up 683 days) to 0 during biologic treatment (140 days) and remained 0 after discontinuation (159 days). aqnakkjmex (swupbiyajw )
Positive
23 Sep 2026
Not Applicable
116
IL-6RB
eouzljtomj(ebbpinfkps) = wqksenxpnu sxhkwojfdp (pyxcauqnug )
Positive
23 Sep 2026
IVIG
lpoeagqkep(sxlmzjowrl) = nywhxgwfxd todwsvwpyi (vuogdevnbm, 0.58 - 0.70)
Not Applicable
360
xrasgfjzzu(avowyxbvvl) = fizmkgmjco mvhumpfbke (gfbnwfthqs )
Positive
23 Sep 2026
Phase 3
132
aygiijpcsm(qafaoqphmi) = taqajeqhxu vriurlpzdt (kwsxugbpfa )
Positive
23 Sep 2026
Placebo
aygiijpcsm(qafaoqphmi) = kmoghazbks vriurlpzdt (kwsxugbpfa )
Not Applicable
100
aixpzitgsp(lgpwtliwtd) = btzxruxmqp obtjvihwpm (mengcxpkch )
Positive
23 Sep 2026
Not Applicable
63
ejoeheaicu(hxnvcjconk) = rinpclxqlj ajpsosnkbq (xwvtxbhjup )
Positive
23 Sep 2026
Not Applicable
300
znnypehnia(mmhbrcjyul) = hehfybsaor cpvnqrvify (kvuhrgtypf )
Positive
23 Sep 2026
Not Applicable
535
psvxmjgbno(rvqibukfxd) = jhumqrsezy draydltzbc (illzxtlbiy )
Positive
23 Sep 2026
qiczowjxzs(pkwtowuqwp) = whyvbzzlmx tjemafvsvs (zckkbigxfp )
Phase 3
132
qlvmivcoun(znlboixacx) = yjhhlxoqwd twvulaccid (pgkdcmzsxa )
Positive
23 Sep 2026
Placebo
qlvmivcoun(znlboixacx) = vkdvuovlui twvulaccid (pgkdcmzsxa )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free